Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evicel as an adjunct to sutured dural repair in elective cranial surgery
2009-016501-41Phase 3Completed
- Sponsor
- OMRIX Biopharmaceuticals, Inc.
- Start
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of porcine fibrin sealant in dural defect, cerebrospinal fluid leak and None (2 arms), sponsored by OMRIX Biopharmaceuticals, Inc. Primary endpoints: Watertight closure at dural repair and Post-operative cerebrospinal fluid leakage by Day 5. Started Dec 2009; status: completed.
02
Drugs
porcine fibrin sealant
03
Conditions
dural defectcerebrospinal fluid leak
Beyond the preview
Go deeper on 2009-016501-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016501-41.